Research programme: anti-plasmacytoid dendritic cell antibodies - SBI Biotech

Drug Profile

Research programme: anti-plasmacytoid dendritic cell antibodies - SBI Biotech

Alternative Names: anti-BST2; SBI-9674; SBI3150

Latest Information Update: 31 Jan 2017

Price : $50

At a glance

  • Originator SBI Biotech
  • Developer Kyowa Hakko Kirin; SBI Biotech
  • Class Antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; Systemic lupus erythematosus
  • Discontinued Cancer

Most Recent Events

  • 31 Jan 2017 Preclinical development is ongoing in Autoimmune disorders and in systemic lupus erythematosus (SBI Biotech pipeline, January 2017)
  • 10 Jan 2017 Kyowa Hakko Kirin in-licenses SBI 9674 from SBI Biotech (SBI Biotech pipeline, January 2017)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top